Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adial Pharmaceuticals, Inc - Common Stock (NQ: ADIL )

0.7200 +0.0200 (+2.86%)
Streaming Delayed Price Updated: 10:16 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,584
Open 0.7400
Bid (Size) 0.6800 (26)
Ask (Size) 0.7300 (26)
Prev. Close 0.7000
Today's Range 0.7100 - 0.7400
52wk Range 0.5759 - 3.000
Shares Outstanding 20,298,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
Adial Pharmaceuticals secured FDA support for its AD04 bridging strategy, paving the way for Phase 3 trials in 2025 after confirming bioequivalence. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-32.11%
-32.11%
1 Month
+1.41%
+1.41%
3 Month
-25.31%
-25.31%
6 Month
-32.71%
-32.71%
1 Year
-57.65%
-57.65%

More News

Read More
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Via Benzinga
Exposures Product Safety
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
ADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024
Via InvestorPlace
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4
Via Benzinga
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Is Serve Robotics (SERV) Stock Down Today?
Via InvestorPlace
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
Via InvestorPlace
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
Via InvestorPlace
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder
Via Benzinga
ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023
Via InvestorPlace
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
Via Benzinga
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
Via ACCESSWIRE
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Via InvestorPlace
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.